Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?

References

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. JCO. 1998;16:2780.
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64:928.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010;116:3843.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32:3059–3067.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology [cited 2016 Jan 17]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Guckenberger M, Alexandrow N, Flentje M. Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation. Radiat Oncol. 2012;7:103.
   PubMed Web of Science ®Google Scholar
• Herfarth K, Engelhard M, Borchmann P, et al. Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG) ASH 2012, Abstract 1634.
   Google Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. JCO. 2012;30:3368.
   PubMed Web of Science ®Google Scholar
• Pendlebury S, el Awadi M, Ashley S, et al. Radiotherapy results in early stage low grade nodal non-Hodgkin’s lymphoma. Radiother Oncol. 1995;36:167–171.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Fuller LM, Velasquez WS, et al. Stage I-II follicular lymphoma. Treatment results for 76 patients. Cancer. 1986;58:1596.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. JCO. 1996;14:1282.
   PubMed Web of Science ®Google Scholar
• Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51:1219.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010 Aug 15;116:3797–3806.
   PubMed Web of Science ®Google Scholar
• Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. JCO. 2004;22:6521.
   Web of Science ®Google Scholar
• MacManus M, Fisher R, Roos D, et al. Treatment with 6 cycles of CVP or R-CVP after involved field radiation therapy (IFRT) significantly improves progression-free survival compared to IFRT alone in stage I-II low grade follicular lymphoma: results of an international randomized trial. Presented at: 2016 ASTRO Annual Meeting; Boston, Massachusetts, 25–28 September 2016.
   Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. JCO. 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• Wohrer S, Jaeger U, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17:780–784.
   PubMed Web of Science ®Google Scholar
• Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–183.
   PubMed Web of Science ®Google Scholar
• Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108–2112.
   PubMed Web of Science ®Google Scholar
• Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:2307–2314.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep. 1977;61:1023–1027.
   PubMedGoogle Scholar
• Yahalom J. Radiotherapy of follicular lymphoma: updated role and new rules. Curr Treat Options Oncol. 2014;15:262–268.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86–92.
   PubMed Web of Science ®Google Scholar
• Perry C, Lerman H, Joffe E, et al. The value of PET/CT in detecting bone marrow involvement in patients with follicular lymphoma. Medicine (Baltimore). 2016;95:e2910.
   PubMed Web of Science ®Google Scholar